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ABSTRACT
The identification of new targets for systemic therapy of hepatocellular carcinoma 
(HCC) is an urgent medical need. Recently, we showed that hNatB catalyzes the N-α-
terminal acetylation of 15% of the human proteome and that this action is necessary 
for proper actin cytoskeleton structure and function. In tumors, cytoskeletal changes 
influence motility, invasion, survival, cell growth and tumor progression, making the 
cytoskeleton a very attractive antitumor target. Here, we show that hNatB subunits 
are upregulated in in over 59% HCC tumors compared to non-tumor tissue and 
that this upregulation is associated with microscopic vascular invasion. We found 
that hNatB silencing blocks proliferation and tumor formation in HCC cell lines in 
association with hampered DNA synthesis and impaired progression through the 
S and the G2/M phases. Growth inhibition is mediated by the degradation of two 
hNatB substrates, tropomyosin and CDK2, which occurs when these proteins lack 
N-α-terminal acetylation. In addition, hNatB inhibition disrupts the actin cytoskeleton, 
focal adhesions and tight/adherens junctions, abrogating two proliferative signaling 
pathways, Hippo/YAP and ERK1/2. Therefore, inhibition of NatB activity represents an 
interesting new approach to treating HCC by blocking cell proliferation and disrupting 
actin cytoskeleton function.
INTRODUCTION
Acetylation is a post-translational modification 
of cellular proteins consisting of covalent binding of an 
acetyl group from an acetyl-CoA donor. This reaction is 
catalyzed by two families of acetyltransferases: lysine 
acetyltransferases (KATs) [1] and alpha-aminoterminal 
acetyltransferases (NATs) [2]. The NAT family has 
6 enzymatic complexes, the majority of which are 
formed by a catalytic and an auxiliary subunit. NATs 
acetylate co-translational nascent polypeptides and each 
complex targets distinct amino-terminal protein sequences 
selected based on the first two aminoacids [2]. The hNatB 
enzymatic complex, which is composed of an NAA20 
catalytic moiety and an NAA25 accessory subunit, 
acetylates all proteins with a glutamine, asparagine, 
glutamic acid or aspartic acid residue immediately after 
the initial methionine [3].
It has been shown that the expression of NAT 
subunits is deregulated in tumor samples and that NAT 
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complexes are required for the proliferation and survival 
of some cancer cell lines [4]. Upregulation of the NatA 
catalytic subunit, NAA10, has been reported in lung, 
breast and urinary bladder cancers as well as in cervical 
carcinoma and HCC in association with poor survival 
and tumor aggressiveness [5]. Additionally, the NatA 
accessory subunit NAA15 was found to be upregulated in 
rapidly progressing neuroblastomas and in undifferentiated 
papillary thyroid carcinomas [6, 7]. Conversely, NAA10 
downregulation may favor the progression of other tumors 
and its upregulation was reported to be associated with 
better prognosis, smaller tumors and reduced metastasis 
[8]. Moreover, NatD has been found to be significantly 
downregulated in hepatocellular carcinoma samples 
and is implicated in apoptosis regulation [9, 10], while 
the NatC catalytic subunit NAA30 is highly expressed 
in glioblastoma patients [11]. Our group has previously 
shown that in HCC, the expression of the NatB catalytic 
subunit NAA20 correlates with tumor progression 
[12]. In addition several authors have observed a direct 
correlation between NatB subunits expression and cellular 
proliferation [13, 14].
In cancer cells cytoskeletal function is essential for 
cell division, cell migration and cellular transformation, 
thus representing an attractive target for antitumor therapy. 
Because inhibitors of actin microfilament polymerization 
are highly toxic due to their inability to discern between 
the tumor actin cytoskeleton and sarcomeric actin 
filaments, attention has been focused on actin regulatory 
proteins, as they are differentially expressed in tumor and 
normal cells [15]. Tropomyosins are actin cytoskeleton 
regulatory proteins possessing high number of isoforms 
resulting from either different gene products or alternative 
splicing [16]. Tropomyosin forms head-to-tail homo- 
or heterodimers along actin filaments regulating their 
biophysical properties and interactions with other actin 
binding proteins in an isoform specific manner [16]. We 
have previously reported that NatB activity is crucial for 
the maintenance of actin filaments structure and function 
by acetylating tropomyosin at its amino terminus, a 
modification in some long tropomyosin isoforms that is 
required for interacting with actin-binding proteins or 
modulate actin-binding and polymerization [3, 17]. In 
contrast, it has been shown that the actin cytoskeleton is 
required for cell cycle progression and that disruption of 
actin filaments causes G1 arrest and impaired cytokinesis, 
which is in agreement with its role in spindle formation 
and contractile ring formation. In addition, actin is also 
implicated in cell signaling pathways, including Hippo, 
Ras-MAPK, PI3K and NF-kB, that are critical in the 
control of cell growth, cell size and cell motility. 
In the present study, we analyzed the potential 
role of NatB-mediated protein alpha-aminoterminal-
acetylation in the growth and progression of HCC. We 
observed that hNatB is upregulated in large number 
of human hepatocellular carcinomas in correlation 
with microvascular invasion. We found that hNatB is 
required for N-α-terminal acetylation of two tropomyosin 
isoforms, tropomyosin 1.6 (TPM 1.6) and tropomyosin 2.1 
(TPM 2.1) and that inhibition of hNatB causes the 
disruption of focal and intercellular adhesions, blocking 
cell cycle progression in association with degradation of 
CDK2, a cyclin-dependent kinase that is also a hNatB 
substrate. Our data suggest that NatB inhibition may be a 
novel and promising approach for the treatment of HCC.
RESULTS
NatB subunits are upregulated in human 
hepatocellular carcinoma
In a previous work we found an increased expression 
of the NatB catalytic subunit, NAA20, in mouse and 
human HCC [12]. To better define the role of hNatB in 
human HCC development we have now analyzed both 
NAA20 and NAA25 protein expression in paired tumor 
and non-tumor samples from 27 HCC patients (74% stage 
BCLC A and 26% stage B) treated with liver resection 
or transplantation (Figure 1, Supplementary Figure 1). In 
59% of patients hNatB subunits were upregulated in tumor 
tissue compared to non-tumor tissue while 33% presented 
reduced tumor expression of both NatB components. 
Most samples manifesting hNatB upregulation showed 
increased expression of both NatB subunits (11 of 16 
samples) and only 4 samples exhibited enhanced levels 
of the catalytic moiety in isolation. To our knowledge 
there are no previous data regarding the upregulation of 
the complete NAT complex in connection to development 
of human tumors. Interestingly we observed a significant 
correlation between upregulation of the two NatB subunits 
and microscopic vascular invasion (p = 0.04) indicating 
that increased levels of the hNatB enzymatic complex 
in HCC can predict poor prognosis. No association 
was found between NatB expression and tumor stage, 
multinodularity or tumor cell differentiation. 
NatB activity controls the structure and function 
of the actin cytoskeleton in HCC
PLC/PRF/5 cells transfected with a negative control 
siRNA (siControl) or NAA20 and NAA25 siRNAs (sihNatB) 
were analyzed 96 hours later with specific antibodies 
for immunofluorescence (Figure 2A, Supplementary 
Figure 2) and western blot analysis. We found that hNatB 
knockdown, which reduces NatB-targeted N-terminal 
acetylation [3], caused a marked decrease in focal 
adhesions (Figure 2A, 2B) without affecting the amount 
of vinculin present in the cells, indicating redistribution 
of this focal adhesion protein (Figure 3C). These 
changes were associated with downregulation of RHOA 
(Figure 3C), a protein that regulates the formation of actin 
stress fibers and focal adhesion complexes [18].
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We observed that TPM 1.6/1.7 and TPM 2.1 
expression was affected upon NatB silencing in PLC/
PRF/5 cells, with some variations among experiments 
(Figure 3C, 3D). This manoeuvre induced a decrease in 
TPM 2.1 protein without modifying its gene expression 
and an increase in TPM 1.6/1.7 gene expression with a 
slight reduction in protein abundance (Figure 3C, 3D, 
Supplementary Figure 3A). MG-132 mediated proteasome 
inhibition resulted in restoration of TPM 2.1 to normal 
levels and an increased abundance of TPM 1.6/1.7, 
indicating that the amino-terminal acetylation of these 
proteins is needed for their stability (Figure 3D). 
Epithelial cells are connected through intercellular 
tight junctions and adherens junctions that require an 
intact actin and cytoskeletal system for proper structure 
and function [19]. Adherens junctions transmit the tensile 
forces from outside of the cell to the actin cytoskeleton, 
while tight junctions separate the apical and the basolateral 
cell surface domains to maintain cell polarity. We therefore 
studied whether hNatB inhibition affects the integrity of 
adherens and tight junctions. We found that hNatB silencing 
caused a reduction in the TJP1 protein at the cell-cell 
interaction points (Figure 2C), which disappeared in some 
stretches (Figure 2A), revealing profound disruption of 
tight junctions. Moreover, occludin, another tight junction 
component, suffered similar distribution upon hNatB 
knockdown (Supplementary Figure 2). To characterize 
the fate of adherens junctions when hNatB was silenced, 
we analyzed the location of β-catenin in PLC/PRF/5 cells 
(Figure 2C). We observed that in control cells, β-catenin 
is predominantly located at the cellular edge associated 
with intercellular regions while in hNatB-deficient cells, it 
is partially relocated to the cytoplasm, revealing adherens 
junctions disorganization (Figure 2D). Interestingly, 
the accumulation of β-catenin in the cytoplasm is not 
accompanied by increased β-catenin transcriptional 
activity, as the expression of its target genes CCND1 and 
AXIN2 (Supplementary Figure 3C), is unmodified.
Quantification of the cell area revealed that hNatB 
knockdown in PLC/PRF/5 cells significantly increased the 
cell surface to almost twice its baseline (Figures 2A, 3A). 
One of the main signaling pathways that regulates cell size 
is the mTOR pathway [20]. Ribosomal Protein S6 (RPS6) 
was phosphorylated upon hNatB silencing indicating 
that deficient hNatB function promotes mTOR activation 
(Figure 3B).
Figure 1: hNatB protein expression in human hepatocellular carcinoma (HCC) and non-tumor liver tissue. (A) Western 
blot of hNatB subunits, NAA20 and NAA25, in the non-tumor (NT) and tumor (T) liver tissue of patients with HCC. Images were quantified, 
normalized with obtained actin values and compared NT vs T paired samples, being considered NT sample as 1. (B) Relationship between 
NAA20 and NAA25 expression and HCC characteristics. 
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hNatB knockdown promotes CDK2 degradation 
and blocks cellular proliferation and tumor 
growth 
In three different HCC cell lines hNatB silencing 
abated cellular proliferation (Figure 4A Supplementary 
Figure 6A), as has been observed in yeast, neurons and 
other human tumor cell lines [13, 14] and blocked DNA 
synthesis, as estimated by reduced EdU incorporation 
(Supplementary Figure 4). In cells synchronized at the 
G1/S phase transition with double thymidine treatment, 
hNatB inhibition hampered progression to the S phase, 
maintaining the percentage of cells in each phase of the 
cell cycle, while control cells exhibited dynamic cell 
Figure 2: Effects of hNatB downregulation on focal adhesions and cell-cell interactions on PLC/PRF/5 cells. PLC/
PRF/5 cells were transfected with negative control siRNA (siControl) or hNaa20 and hNaa25 siRNAs (sihNatB) and 96 hours later were 
paraformaldehyde fixed and analyzed with specific antibodies for immunofluorescence analysis (A) with specific antibodies for focal 
adhesions (vinculin) and cell-cell contacts: tight junctions (TJP1) and adherens junctions (β-catenin). (B) Focal adhesions were analyzed 
and the number of adhesions per micron2 were quantified. (C) TJP1 presence was quantified from the cell-cell contact point to 7mm inside 
the cell (n = 10). (D) For β-catenin distribution quantification cells were transformed into circular surfaces, divided in 5 concentric circular 
rings with an equal surface ranging from the cell center (centroid) to the cell membrane (Edge) and % of β-catenin present in each region 
was quantified (n > 21). The data are presented as the mean ± SME. Statistical significance is shown in figure panels and it was set at 
p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) value. Unpaired (B, D) and paired t-test (C) were performed. Scale bar: 25 µm.
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Figure 3: Effects of hNatB downregulation on cell size and actin cytoskeleton protein expression on PLC/PRF/5 cells. 
(A) Cell spread area corresponds to the average cell surface in mm2 in both experimental conditions (n > 29). (B) mTOR activation was 
evaluated 96 hours after siRNAs transfection studying Ribosomal S6 protein (P-RPS6) by western blot in cell lysates. (C) PLC/PRF/5 
cells transfected with negative control siRNA (siControl) or NAA20 and NAA25 siRNAs (sihNatB) lysates were harvested at different time 
points after transfection and western blot analysis was performed using antibodies against RHOA, tropomyosins, Vinculin, E-Cadherin, 
cofilin and β-catenin. Actin was used for normalizing extracts and NAA20 and NAA25 to verify NatB downregulation. (D) Tropomyosin 
expression was evaluated by western blot in PLC/PRF/5 cells 96 hours after siNatB (+) and siControl (−) transfection. Cells were treated 
with proteasome inhibitor MG132 (1 mm) or DMSO for 4 or 8 hours and then cell lysates were prepared. The data are presented as the 
mean ± SME. Statistical significance is shown in figure panels and it was set at p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) value. Paired 
t-test was performed. 
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cycle progression (Figure 4B). The disturbance of the 
cell cycle in hNatB-deficient cells was also revealed by 
observing impairement of DNA synthesis and alteration of 
dynamic Cyclin A2 and Cyclin B1 expression and CDC2 
phosphorylation at different time points after releasing 
DNA synthesis blockade (Supplementary Figure 5).
To gain insight into the molecular mechanisms 
interfering with cell proliferation upon hNatB inhibition, 
we analyzed several cell cycle regulators at different time 
points after transfecting PLC/PRF/5 cells with anti-hNatB 
and control siRNAs (Figure 4C). We found that pRb was 
similarly expressed in control and hNatB-deficient cells 
while protein levels of CDK2, a key regulator of the S 
to G2/M phase transition, were markedly decreased 
after hNatB suppression. Interestingly, CDK2 mRNA 
levels remained unchanged (Supplementary Figure 3B) 
suggesting that the CDK2 protein was unstable in the 
absence of functional hNatB. CDK2 is a hNatB substrate 
that depends on this enzyme for its N-terminal acetylation 
[3]. To evaluate CDK2 stability in hNatB-deficient cells 
we overexpressed CDK2 in PLC/PRF/5 cells that had been 
treated with either anti-hNatB siRNA or control siRNA 
and found a marked decrease in CDK2 protein levels 
(Figure 4D). Interestingly, we also observed that reduced 
levels of CDK2 after hNatB inhibition in PLC/PRF/5 
cells can be reversed by treatment with a proteasome 
inhibitor (Figure 4E), indicating that N-terminal 
acetylation is critical for CDK2 stability. Several groups 
have independently demonstrated that CDK2 inhibition 
causes a delay of the G2 phase and deregulation of CDC2/
Cyclin B1 activity [21, 22]. Accordingly, we observed 
that CDK2 reduction is associated with upregulation of 
Cyclin A2 and Cyclin B1 and increased phosphorylation 
of WEE1 (Ser-642) and CDC2 (Tyr-15) 72 hours after 
siRNA transfection (Figure 4C). These data are consistent 
with restriction of late S phase and G2-M phase transition, 
in agreement with our observations in synchronized cells 
using cell cycle FACS analysis.
Since the above findings pointed to hNatB as a 
potential therapeutic target for HCC, we analyzed whether 
hNatB downregulation could reduce the tumorigenicity of 
human hepatocellular carcinoma cell lines subcutaneously 
inoculated in xenograft mouse models (Figure 4F). We 
found that the suppression of hNatB expression completely 
abolished the ability of Huh7 cells to form tumors 
and markedly reduced the volume of PLC/PRF/5 and 
Sk-Hep1 tumors seven weeks after cell transplantation. 
Similarly, when we treated PLC/PRF/5 cells with an 
actin depolymerizing agent, such as Cytochalasin B, 
which blocks cell proliferation and has antitumor activity 
[23], transplanted cells formed subcutaneous tumors as 
efficiently as control cells. Therefore, abrogation of hNatB 
activity could present a more pronounced and stable 
antitumor effect than Cytochalasin B.
Disruption of ERK1/2 and Hippo signaling 
pathways in hNatB depleted cells
The impairment of tumor cell proliferation and 
cytoskeletal function observed in hNatB-depleted HCC 
cells led us to investigate critical signaling molecules 
involved in cellular responses to growth factors and 
mechanical stimuli, including the ERK1/2 and Hippo/
YAP pathways. We found that hNatB knock-down 
markedly reduced ERK1/2 phosphorylation at 72 h 
and 96 h after siRNA transfection (Figure 5A) and that 
EGF-induced ERK1/2 activation was severely blunted 
in hNatB-deficient cells (Figure 5B, Supplementary 
Figure 6B). In a multicellular context, mechanical forces 
are the dominant regulators of the activity of YAP, a highly 
oncogenic transcription factor expressed in HCC [24]. 
YAP is transcriptionally active when it is localized in the 
nucleus, and it is inactive in the cytoplasm. We observed 
that YAP is localized predominantly in the nucleus in 
control cells but shuttles to the cytoplasm upon hNatB 
silencing (Figure 5C). When we examined several of the 
main components of the Hippo pathway, we observed that 
hNatB downregulation induced Mob-1 phosphorylation, 
which is an event associated with YAP inhibition [24] 
(Figure 5D). To verify whether hNatB depletion reduces 
YAP transcriptional activity we analyzed two YAP target 
genes, ANKRD1 and CTGF in PLC/PRF/5 and Huh7 cell 
lines (Figure 5E) and found that both genes were markedly 
downregulated, confirming that the YAP pathway is 
inactivated when hNatB is inhibited. Taken together, these 
findings indicate that both the ERK1/2 and YAP pathways 
are abrogated when hNatB is inhibited.
Tropomyosin dysfunction partially mediates the 
anti-oncogenic effects of hNatB inhibition 
Previous studies have shown that one of the main 
consequences of NatB knockdown in yeast, flies and 
mammalian cells is functional impairment of tropomyosin 
due to absent N-terminal acetylation [3, 25, 26]. We then 
investigated the implication of TPM 2.1 and TPM 1.6 in 
the disruption of the cell cycle and the actin cytoskeleton in 
HCC cells when hNatB expression was suppressed. Cells 
transduced with control or NAA20 and NAA25 siRNAs 
were transfected with expression vectors expressing 
luciferase (Luc), tropomyosin 1.6 (TPM 1.6), tropomyosin 
2.1 (TPM 2.1) or both tropomyosins (TPM 1.6 + TPM 2.1). 
After 72 hours, cell proliferation, focal adhesions and cell-
cell contacts were evaluated (Supplementary Figure 7). 
We found that co-overexpression of both TPM 1.6 and 
TPM 2.1 induced partial recovery of the proliferative 
activity of hNatB-silenced PLC/PRF/5 cells (Figure 6A). 
Accordingly, TPM 1.6 and TPM 2.1 co-overexpression 
was not enough to normalize the expression of cell cycle 
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Figure 4: NatB is required for proper cell cycle progression and tumor growth. PLC/PRF/5 cells were transfected with 
negative control siRNA (siControl) or hNaa20 and hNaa25 siRNAs (sihNatB) and 96 hours later proliferation rate was determined based 
on Cell Titer-Glo (A). siRNA transfected PLC/PRF/5 cells were synchronized in the early S phase with doble thymidine treatment, wash 
and analyze them by FACS 0, 2, 5 and 11 hours later. Before cells collection, they were incubated for 1 hour with Edu for DNA synthesis 
quantification (B). PLC/PRF/5 cell extracts were analyzed by western blot 48, 72 and 96 hours after transfection of control (siControl) and 
NAA20 and NAA25 (sihNatB) siRNAs visualizing diverse proteins that regulate cell cycle progression (C). In addition cells treated with 
control siRNAs or siNAA20 and siNAA25 (sihNatB) were transfected with CDK2 or luciferase (Luc) expression vectors and overexpressed 
CDK2 was analyzed by western blot (D). CDK2 expression was evaluated by western blot in PLC/PRF/5 cells 96 hours after siNatB (+) and 
siControl (−) transfection. Cells were treated with proteasome inhibitor MG132 (1 mm) or DMSO for 4 or 8 hours and then cell lysates were 
prepared (E). Half million cells were subcutaneously injected into the flank of immunodeficient mice 48 hours after siRNA transfection or 
Cytochalasin B treatment and tumor volume was determined 60 days after cell inoculation (F). The data are presented as the mean ± SME 
of three experiments. Statistical significance is shown in figure panels and it was set at p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) value. 
Unpaired t-tests were performed.
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regulating proteins, such as Cyclin B1 and Cyclin A2, or 
ERK1/2 and WEE phosphorylation, which is deregulated 
when hNatB is inhibited (Figure 6B). However, TPM 1.6, 
and to lesser extent TPM 2.1, was sufficient to reconstitute 
focal adhesions (Figure 6C) and TPM 2.1, but not TPM 
1.6, expression restored β-catenin localization, normalizing 
its presence at the edge of the cell (zone 5) and in the cell 
cytoplasm (zones 2 and 3) (Figure 6D). Moreover, TPM 
2.1 reconstitutes TJP1 distribution at the cell-cell junction, 
indicating that adherens junctions and tight junctions 
share a role for TPM 2.1 in maintaining their structure 
(Figure 6E). Additionally, co-overexpression of both 
tropomyosins, TPM2.1 and TPM1.6, is required to 
reverse the effects of hNatB inhibition on cell size and 
mTOR activation, linking cell proliferation and size 
(Figure 6B, 6F). 
Figure 5: ERK1/2 and Hippo/YAP signaling pathways are inactivated when NatB is inhibited. PLC/PRF/5 cell lysates were 
prepared and ERK1/2 activation was analyzed by western blot 48, 72 and 96 hours after siRNA transfection (A) or after treating the cells 
with EGF (50 ng/ml) for 30, 60 and 120 minutes (B). YAP localization was studied by immunofluorescence in PLC/PRF/5 cells transfected 
with siControl and siNAA20 and siNAA25 (sihNatB) siRNAs 96 hours after transfection (C). Hippo/YAP pathway activation was studied 
by western blot in PLC/PRF/5 cell lysates obtained 48, 72 and 96 hours after siRNA transfection (D) and analyzing ANKRDT1 and CTGF 
mRNA expression by RT-PCR 96 hours after siRNA transfection (E). The data are presented as the mean ± SME of three experiments. 
Statistical significance is shown in figure panels and it was set at p < 0.05 (*) and p < 0.01 (**) value. Unpaired t-tests were performed. 
Scale bar: 25 µm.
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Figure 6: Tropomyosin 2.1 and 1.6 functional deficiencies mediate proliferation and cytoskeletal defects associated 
with hNatB downregulation. PLC/PRF/5 cells transduced with control (siControl) and NAA20 and NAA25 (sihNatB) siRNAs were 
transfected with expression vectors for luciferase (Luc), tropomyosin 1.6 (TPM 1.6), tropomyosin 2.1 (TPM 2.1) or both tropomyosins 
(TPM 1.6 + TPM 2.1). 72 hours after siRNA transfection cell proliferation was evaluated with Cell Titer-Glo viability Assay (n = 3) (A) and 
24 hours later cell lysates were prepared and cell cycle regulating proteins were analyzed by western blot (B). In addition, 96 hours after 
siRNA transfection cells were fixed and stained for immunofluorescence analysis. Focal adhesions (Vinculin), tight junctions (TJP-1) and 
adherens junctions (β-catenin) were visualized and the number of adhesions per micron2 (≥ 13626 mm2 n ≥ 7) (C), percentage of β-catenin 
located in equal cell concentric areas (n ≥ 21) (D) and TJP-1 presence at the cell-cell contact point (n ≥ 10) (E) were quantified. Cell spread 
area corresponds to the average cell surface in mm2 in all experimental conditions (n ≥ 29) (E). The data are presented as the mean ± SME. 
Statistical significance is shown in figure panels and it was set at p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) value.
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TPM 1.6 and TPM 2.1 N-terminal acetylation 
is required for maintaining focal adhesions, tight and 
adherens junctions structure, proper cell size and cell 
proliferation in HCC cells.
DISCUSSION
N-terminal acetylation is a co/post-translational 
modification of proteins that is essential for their stability 
and function. hNatB mediates N-terminal acetylation of 
specific proteins, which are recognized by specific amino 
acid sequence at the N-terminus. There is an increasing 
number of proteins that depend on their N-terminal 
acetyl group for proper functioning [27], including 
NatB substrates [28, 29]. Here, we show that hNatB is 
upregulated in a substantial proportion of HCC tumors and 
that this occurs in association with microscopic vascular 
invasion. Microscopic vascular invasion is a morphological 
feature linked to tumor progression and poor prognosis 
[30], and it is characterized by the presence of tumor 
emboli in a portal radicle vein, large capsule vessels or 
in a vascular spaces lined with endothelial cells [31]. 
Interestingly, both subunits were up- or downregulated in 
74% of analyzed tumor samples, indicating the expression 
of both subunits is co-regulated probably as a consequence 
of NAA20 degradation when it is not interacting with 
the accessory subunit NAA25 [13]. In vitro studies 
aimed at analyzing whether an hNatB blockade could 
exert anti-oncogenic effects on HCC showed that hNatB 
depletion reduces N-terminal acetylation on proteins [3] 
and it caused marked cytoskeletal dysfunction in HCC 
cells accompanied by impaired proliferation and cell 
cycle progression. Upregulation of NatB expression in 
HCC can increase tumor cell aggressiveness facilitating 
microvascular invasion as consequence of an increased 
proliferation rate or invasion potential. 
Consistently, it was found that suppression of hNatB 
expression in human hepatocellular carcinoma PLC/PRF/5 
cells caused profound reduction in the levels of both 
tropomyosin isoforms and CDK2, two hNatB substrates 
that are critical regulators of cytoskeletal function and 
cell cycle progression, respectively. However, their gene 
expression is either not affected (CDK2, TPM 2.1) or 
increased (TPM 1.6/1.7) indicating that their stability is 
impaired when they are not acetylated on the N-terminal 
residues. Accordingly, previous reports have suggested 
that protein stability comes from the N-terminus, which 
is governed by the N-end rule pathway that associates 
the half-life of a protein to the identity of its N-terminal 
residue [32].
Abundant evidence in a variety of cell types from 
yeast to humans, shows that tropomyosin N-terminal 
acetylation is essential for a functional actin cytoskeleton 
[3, 25, 26, 33, 34]. It has been shown that N-terminal 
acetylation of tropomyosin stabilizes the coiled-coil 
formation in the first 30 amino acids, which is essential 
for tropomyosin to assemble around the actin filaments 
[35]. Accordingly, the fusion of a peptide to the N-terminal 
end of TPM 2.1 disrupts dimer formation, and this 
prevents TPM2.1 from binding to F-actin, which results 
in cytoskeleton disorganization and delayed cytokinesis 
[36]. In agreement with these findings, a genetic linkage 
between the NatB subunits and tropomyosin in yeast 
and flies also suggests a functional interaction between 
these proteins [34, 37]. Several studies demonstrated 
that tropomyosin has essential roles in focal adhesions 
and stabilization of cell-cell junctions [16]. We have 
shown that two tropomyosin isoforms, TPM 1.6 and 
TPM 2.1, depend on N-terminal acetylation to be stable 
and functional and are important for focal adhesion 
formation in hepatoma cells whereas TPM 2.1 is involved 
in maintaining adherens and tight junction structure, 
retaining TJP1 and β-catenin at the cell-cell junctions. 
Indeed it has been reported that TPM 2.1 is part of focal 
adhesion structure, while TPM 1.6/1.7 integrates with 
actin stress fibers that generate focal adhesions [17].
The actin cytoskeleton is implicated in the control of 
numerous signaling pathways that govern cell proliferation 
[38]. Two pathways connecting mechanical forces and cell 
growth are the Ras-MAPK-ERK and Hippo pathways, 
and these require functional actin filaments to control cell 
proliferation [24, 39]. Importantly, we found that hNatB 
silencing abrogated both ERK1/2 phosphorylation in non-
stimulated HCC cells and ERK1/2 activation in EGF-
stimulated cells. Along with ERK inactivation, hNatB 
inhibition resulted in degradation of the oncogene YAP 
degradation and downregulation of YAP target genes. 
These effects were accompanied by impeded formation of 
actin fibers and a consequential blockade of cytoskeleton-
associated functions, such as cellular motility, cellular 
interaction with the extracellular matrix, cell-cell contacts 
and cell proliferation. 
Several reports have shown an inverse correlation 
between cell proliferation and cell size [40], and inhibition 
of hNatB expression increases cell size and reduces 
proliferation. These two effects are reversed when both 
tropomyosins are co-overexpressed, revealing a link 
between NatB expression, tropomyosin function, cell size 
and proliferation. mTOR and its downstream substrate RPS6 
have been demonstrated to control cell size and proliferation 
[20]. In MEFS, there is an inverse correlation between 
cell proliferation and RPS6 phosphorylation [41], and in 
Xenopus eggs, it was found that Ras-induced cell cycle 
arrest is associated with increased RPS6 phosphorylation 
[42]. We observed that upon hNatB inhibition, the mTOR 
pathway is activated by increased RPS6 phosphorylation 
[20]. Interestingly, RPS6 phosphorylation decreases when 
both tropomyosins are overexpressed supporting the 
concept that tropomyosins mediate the effects of the mTOR 
pathway on cell size and cell proliferation. 
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Our study shows that NatB activity is necessary for 
human hepatoma cell proliferation and tumor formation 
when HCC cells are transplanted subcutaneously in mice. 
In addition to disrupting the actin cytoskeleton, NatB 
ablation impinges on cell cycle dynamics by limiting DNA 
synthesis and progression through the S and G2/M phases. 
hNatB depletion prevents CDK2 N-terminal acetylation, 
making this protein less stable and reducing its cellular 
levels. Inhibition of CDK2 activity arrests cells in late the 
S and G2 phases in association with increased CDC2 Y15 
phosphorylation and inactive Cyclin B/CDC2 [22, 43]. 
Degradation of CDK2 that is not N-terminal acetylated 
is associated with active WEE1 stabilization and CDC2 
inactivation due to blockage of the G2/M transition. 
Moreover, the timing of Cyclin B/CDC2 activation, which 
is essential for driving mitotic events, has been shown to 
be dependent on Cyclin A/CDK2 activity [44], which is 
reduced upon hNatB inhibition.
The actin cytoskeleton is an attractive target for 
anti-cancer chemotherapeutic strategies, but interference 
with actin polymerization was found to be associated with 
intolerable cardiac and respiratory muscle toxicity [15]. 
However, it seems possible that alternative strategies 
directed to alter the function of cytoskeletal regulatory 
proteins might display significant antioncogenic activities 
with acceptable side effects. Here, we have shown that 
impairing tropomyosin function by implementing a NatB 
blockade in tumor cells makes them to stop growing 
and lose tumorigenicity. Interestingly, high molecular 
weight tropomyosin isoforms are downregulated in 
many cell transformation events in association with 
actin cytoskeleton reorganization [45], including HCC 
development [46]. Changes in actin cytoskeleton 
properties in tumor cells, such as reducing the expression 
of high molecular weight tropomyosin isoforms, can 
make these cells more sensitive to modifications that 
reduce tropomyosin function. There is increasing evidence 
of physical interactions between actin cytoskeleton 
components and the signal transduction pathways that 
regulate their function. One tropomyosin isoform, TPM 
3.1, is involved in regulation of the MAPK/ERK signaling 
pathway, helping pERK nuclear translocation and 
governing cell proliferation [47]. We have observed that 
downregulation of NatB expression in an HCC cell line 
reduces TPM 1.6/1.7 and TPM 2.1 levels, which affects 
mTOR signaling but not ERK phosphorylation. There are 
diverse actin filament populations with distinct functions 
partially controlled by actin filaments of tropomyosin 
isoforms [17]. We provide new evidence that supports the 
regulatory role of distinct signal transduction pathways 
in tropomyosin isoforms to define different actin filament 
population functions. 
Our data revealed that NatB inhibition affects 
N-terminal acetylation and function of TPM 1.6/1.7, 
TPM 2.1 and CDK2, leading to dysfunction of the actin 
cytoskeleton, impairment of cell cycle progression and 
abolition of tumorigenicity. Thus, the hNatB blockade 
represents a new avenue deserving consideration for the 
treatment of advanced hepatocellular carcinoma.
MATERIALS AND METHODS
Human liver samples
27 paired samples of HCC and NT tissue were 
obtained from patients who underwent curative surgical 
resection and donated samples to the University of Navarra 
Biobank. Tumors were classified as Barcelona Clinic Liver 
Cancer (BCLC) stage A (74%) and B (26%). All patients 
provided written informed consents, the study protocol 
conformed to the ethical guidelines of the 1975 Declaration 
of Helsinki was approved by institutional review board 
of University of Navarra (065-2012) and samples were 
provided by the University of Navarra Biobank (BB-13-01). 
Informed consent was obtained from each patient and the 
study protocol conformed to the ethical guidelines of the 
1975 Declaration of Helsinki as reflected in a priori approval 
by the appropriate institutional review committee.
Antibodies
Antibodies recognizing cofilin (FL166), p-cofilin 
(H2), p53 (DO-1) and YAP (63.7) were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Antibodies recognizing β-catenin (D10A8), ciclin A2 
(BF683), ciclin B1 (D5C10), ciclin D1 (92G2), p-Cdc2 
(10A11), CDK2 (78B2), E-cadherin (24E10), p-Erk 1/2 
(197G2), YAP (D24E4), LATS1 (C66B5), P-MOB1 
(D2F10), p21 Waf1/Cip1 (12D1), p-Rb (S807/811) 
(#9308), RhoA (67B9) and p-Wee (Ser642) (D47G5 )were 
obtained from Cell Signaling. Erk 1/2 (06-182) antibody 
was from Millipore. Anti-β-actin (A2228) and anti-
vinculin (V9131) antibodies were supplied from Sigma-
Aldrich (St Louis, MO, USA) and anti-ZO-1 (33-9100) 
and anti-Occludin (33-1500) antibodies were obtained 
from Invitrogen. An antibody directed against GAPDH 
(MCA2427) was provided from AbD serotec (BioRad). 
The antibody specifically recognizing Naa20 (158071AP) 
was purchased from Protein Tech and an antibody against 
Naa25 (HPA039322) was purchased from SIGMA. Anti-
α-tubulin (T6199) and anti-tropomyosin (T2780) were 
obtained from SIGMA. The secondary antibodies used 
were anti-rabbit IgG HRPO (Cell Signaling) and an anti-
mouse IgG HRPO (SIGMA).
Cell culture and siRNA transfection
Huh7 (HB-8065), PLC/PRF/5 (CRL-8024) and SK-
Hep1 (HTB-52) were cultured in DMEM supplemented 
with 10% (vol/vol) dialyzed FBS (Invitrogen), 
100 units/mL penicillin (Invitrogen), and 100 µg/mL 
streptomycin (Invitrogen) at 37°C and in 5% CO2. 
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Scrambled control siRNA or siRNAs specifically 
directed against Naa20 and Naa25 were purchased 
from Invitrogen. The siRNAs transfection was carried 
out using RNAiMAX Lipofectamine (Invitrogen) 
in accordance with the manufacturer’s procedures. 
Transfection complexes were added to the cells at a final 
oligonucleotide concentration of 20 nM.
To disturb actin microfilaments, PLC and Huh7 cells 
were grown in the presence of cytochalasin B 0.2 µM 
(Sigma-Aldrich) for the indicated periods of time changing 
the medium every 24 h. The drugs’ diluent (DMSO) was 
used as a negative control.
Immunofluorescence
For staining cytoskeletal proteins cells were fixed 
with 4% (wt/vol) paraformaldehyde for 15 minutes, 
permeabilized with 0.1% Triton X-100 and incubated with 
the following primary antibodies: anti–α-catenin (23B2, 
Cell Signaling), anti- β-catenin (D10A8, Cell Signaling), 
anti-paxillin (sc-5574, Santa Cruz), anti-occludin 
(33-1500, Invitrogen), anti-vinculin (V9131, SIGMA), 
anti-YAP (D24E4, Cell Signaling) and anti-ZO-1 
(33-9100, Invitrogen), followed by incubation with anti-
mouse IgG Cy3 conjugated developed in sheep (Sigma) or 
anti-rabbit IgG Alexa488 conjugate developed in donkey 
(Molecular Probes). All incubations were performed for 
30 min at 37°C. To stain actin stress fibers, cells were 
incubated with Oregon Green 448 phalloidin (Invitrogen) 
for 15 min at 20°C. Stained cells for each preparation 
were mounted with Vectashield Mounting Medium with 
DAPI (Vector Laboratories). Samples were analyzed 
using an Axiovert 200M confocal LSM 510 META Zeiss 
microscope with a 40× objective.
Western blot analysis
Whole-cell lysates were prepared according to the 
established procedures. Proteins were resolved by sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis, 
immunoblotted with the antibody of interest and 
visualized using an ECL chemiluminescence detection 
kit (Amersham Biosciences, Amersham, UK). Obtained 
western-blot bands were quantified using Image Studio 
Lite software. At least three independent experiments were 
carried out with separate samples.
Real-time PCR assays
Total RNAs were extracted with the Trizol 
(Invitrogen, Carlsbad, CA, USA). Reverse transcription 
was performed as previously reported [41]. Real-time 
polymerase chain reactions were performed with iQ 
SYBR Green supermix (Bio-Rad) in a CFX96 Real-
Time System (BioRad), using specific primers for each 
gene: CDK2 F 5′GACACGCTGCTGGATGTCA, R 
5′CGGAAGAGCTGGTCAATCTCA; ANKRD1 F 5′AG 
TAGAGGAACTGGTCACTGG, R 5′TGGGCTAGAAG 
TGTCTTCAGAT; CTGF F 5′AGGAGTGGGTGTGTGA 
CGA, R 5′CCAGGCAGTTGGCTCTAATC; GAPDH 
 F 5´ACCACAGTCCATGCCATCAC, R 5′TCCACCAC 
CCTGTTGCTGTA; TPM2.1 F 5´GACGTCCCAGTC 
CCGCTCCG, R 5′CTCCTGGGCCTCCTTCACGG; 
TPM1.6 F 5′TGGAGCTGGCAGAGAAAAAG, R 5′TTC 
AAGCTCGGCACATTTGC; AXIN2 F 5′AGTGCAA 
ACTTTCGCCAACC, R 5′GGTTCTCGGGAAATGA 
GGTA and CCND1 F 5′CCGCCGAGGAGGAGGAAGA, 
R 5′CCACCGCTCAGGGTTATGCA. The amount of each 
transcript was quantified by the formula: 2ct(β-GAPDH)−ct(gene), 
with ct being the point at which the fluorescence rises 
appreciably above the background fluorescence.
Cell proliferation assay
To determine the rate of cell proliferation, Cell 
Titer-Glo Luminescent Cell Viability Assay Titer-GLO 
kit (Promega) was used. Cells were seeded in 96-well 
plate and transfected with different siRNAs according 
to the protocol described in the previous section. For 
measurement, 50 µl of medium from each well were 
removed and added to 50 µl of CellTiter-Glo proliferation 
reagent. Then, the plate was shaken vigorously on a shaker 
plate for 2 minutes and absorbance of the product formed 
was measured on a luminescence microplate reader 
(Orion, Berthold Detection system).
Analysis of cell cycle distribution
The proliferative capacity of the cells was 
determined by flow cytometry assay using Click-iT 
EdU kit (Invitrogen™/Molecular Probes) following the 
manufacturer’s instructions. Cells were incubated with 
the modified thymidine analogue EdU (5-ethynyl-2′-
deoxyuridine) in the culture medium at a concentration 
of 10 µM to visualize DNA synthesis for 2 hours at 37ᵒC 
and 5% of CO2 in the cell incubator. Incorporated Edu 
was detected with Alexa Fluor 647 azide according to the 
staining protocol provided by Invitrogen. The samples 
were analyzed with BD FACSCanto™ cytometer (BD 
Biosciences) using an excitation wavelength of 633 nm 
and an emission filter of 660 nm. Data were analyzed with 
software version 7.6.3 FlowJo.
For synchronization of cells in the early S phase 
double thymidine block was used. To do this, cells were 
incubated for 14 hours with thymidine 2 mM in the culture 
medium. Then, thymidine medium was removed and 
fresh medium with 24 mM deoxycytidine (Sigma) was 
added and incubated for 9 hours. Thymidine blockade 
and deoxycytidine incubation were repeated once more as 
described above. Then, cells were washed with phosphate 
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buffered saline (Gibco) and cell cycle flow cytometry 
analysis was conducted under the same conditions 
described above, including an additional incubation 
for 1 hour in fresh medium before adding EdU to avoid 
deoxycytidine interference.
Xenograft tumor generation
Animal studies were conducted in accordance with 
the institutional guidelines for care and use of laboratory 
animals and were approved by the competent authority 
(018–11). All animals received humane care according to 
the criteria outlined in the “Guide for the Care and Use of 
Laboratory Animals” prepared by the National Academy of 
Sciences and published by the National Institutes of Health 
(NIH publication 86–23 revised 1985). Animal experiments 
were performed conform to the Animal Research: Reporting 
of In Vivo Experiments (ARRIVE) guidelines. To generate 
xenograft tumors, 5 × 105 siControl or siNatB transfected 
Huh7/PLC/SK-Hep1 cells were subcutaneously injected 
into the right or left of 6–8 week old BALB/c Rag2tm1Fwa 
Il2rgtm1Amk /J male mice (6–7 animals) flank respectively, 
48 hours after siRNA transfection or Cytochalasin B 
(50 µg/ml) treatment. Tumor volumes were calculated 
using the formula: tumor volume (cm3) = 0.52 × (width) 
2 × (length).
Morphometric analysis and quantification of 
focal and cell-cell adhesions
Cell spread areas, the percentage of beta catenin 
intensity per section and vinculin focal adhesion properties 
were quantified using previously described [42] custom-
made code written in Matlab (The Mathworks Inc., Natick, 
MA, USA). 
The percentage of total beta-catenin intensity per 
section was defined as the sum intensity of all pixels 
contained in a section divided by the sum intensity of beta-
catenin across the whole cell. Briefly, to quantify intensity 
independently of cell size or shape, cell morphology was 
first transformed into a uniform circular distribution where 
the center and the perimeter correspond to the cell centroid 
and perimeter, respectively. This circular distribution was 
then divided into five ring-shaped sections of equal area 
from the center to the edge. The resulting sum of each 
section was divided by the sum of the intensity across the 
entire cell [48].
To measure the disruption of tight junctions, a 
custom-made code was written in Matlab to measure 
the local mean ZO-1 intensity across cell-cell adhesions 
of each cell. First, cell-cell adhesions corresponding 
to one cell and the area close to these adhesions were 
segmented. Then, the mean intensity was then quantified 
as a function of the distance to the adhesion. Vinculin 
focal adhesions were segmented and then their area was 
quantified following the same procedure as described 
previously [42].
Statistical analysis
Statistical significance was assessed using Prism 
5 (GraphPad Software) and IBM SPSS Statistics. When 
the number of samples of each variable was under 
10 it was conducted a statistical test for non-parametric 
Student t followed by a U Mann- Whitney test to compare 
two groups. When the number of samples analyzed 
was greater than 10, the statistical significance of the 
differences between groups was determined from the 
mean and the SD using unpaired, two-tailed t test. ZO-1 
distribution statistical significance between the control and 
experimental groups was determined using Shapiro-Wik 
normality test, equal variance test and a paired t-test. The 
number of cells examined for β-catenin distribution was 
≥ 21, for ZO-1 distribution n ≥ 10, for spread area n ≥ 29 
and for focal adhesion analysis ≥ 13626 mm2 and N ≥ 7. 
Statistical significance was set at p < 0.05 (*), p < 0.01 
(**) and p < 0.001 (***) value. 
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